Roquinimex (Standard)

Overview

Roquinimex (Standard) is the analytical standard of Roquinimex ( HY-13743 ). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines ( IL-2 , IFN-γ ), promotes TH2 lymphocyte cytokines ( IL-4 , IL-10 ), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > IFNAR

Product Information

• Catalog No.: HY-13743R
• CAS No.: 84088-42-6
• Molecular Formula: C18H16N2O3
• Molecular Weight: 308.33
• Purity: 98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.
• Availability: In-stock

Source

Original product source